EU Court of Justice’s AstraZeneca judgment may point to more pro-innovator stance

Last week’s judgment from the Court of Justice of the European Union (“CJEU”) in the landmark AstraZeneca v Commission case appeared to represent another resounding victory for the European Commission (“Commission”) and a defeat for the innovative pharmaceutical industry.